The 'Psychedelic Renaissance' Continues | The Libertarian Institute
https://libertarianinstitute.org/articles/the-psychedelic-renaissance-continues/
> In early 2024, Rick Doblin—the man whose work launched one of the biggest social and cultural movements of our time, “the Psychedelic Renaissance”—was expecting to see the crowning achievement of his life’s mission. The non-profit he led and founded, the Multidisciplinary Association for Psychedelic Studies (MAPS), had recently published the second of its Phase 3 clinical trials of the psychedelic drug MDMA, investigating its efficacy in the treatment of Post-Traumatic Stress Disorder (PTSD). The results seemed incontestable.
> The MDMA-assisted therapy developed by Doblin and his team was shown to produce drastic improvement in 72% of patients with PTSD, so that two months after treatment, they no longer met the criteria for the disorder. This made it far and away the most effective treatment available for what is an otherwise largely intractable, debilitating, and potentially fatal mental illness, which afflicts over thirteen million Americans. And this second trial was the last hurdle to be cleared before the drug could receive FDA-approval and become a legal, prescription medication. The FDA-approval of MDMA was the main target Doblin set out to achieve when he founded MAPS four decades earlier.
https://stacker.news/items/1409403
https://libertarianinstitute.org/articles/the-psychedelic-renaissance-continues/
> In early 2024, Rick Doblin—the man whose work launched one of the biggest social and cultural movements of our time, “the Psychedelic Renaissance”—was expecting to see the crowning achievement of his life’s mission. The non-profit he led and founded, the Multidisciplinary Association for Psychedelic Studies (MAPS), had recently published the second of its Phase 3 clinical trials of the psychedelic drug MDMA, investigating its efficacy in the treatment of Post-Traumatic Stress Disorder (PTSD). The results seemed incontestable.
> The MDMA-assisted therapy developed by Doblin and his team was shown to produce drastic improvement in 72% of patients with PTSD, so that two months after treatment, they no longer met the criteria for the disorder. This made it far and away the most effective treatment available for what is an otherwise largely intractable, debilitating, and potentially fatal mental illness, which afflicts over thirteen million Americans. And this second trial was the last hurdle to be cleared before the drug could receive FDA-approval and become a legal, prescription medication. The FDA-approval of MDMA was the main target Doblin set out to achieve when he founded MAPS four decades earlier.
https://stacker.news/items/1409403